Vanda Announces Positive Phase III Study Results for Tasimelteon for Treatment of Non-24-Hour Disorder
Posted on January 23, 2013 at 06:45 AM EST
Vanda Pharmaceuticals (NASDAQ: VNDA ), today announced positive results for the second Phase III study of tasimelteon for the treatment of Non-24-Hour Disorder (Non-24). The RESET study (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder), demonstrated the maintenance effect of 20mg of tasimelteon to